Clarity Pharmaceuticals Partners with SpectronRx for U.S. Manufacturing of Cu-64 SAR-bisPSMA

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.

Clarity Pharmaceuticals has entered into a Commercial Manufacturing Agreement with SpectronRx to produce its lead diagnostic product, Cu-64 SAR-bisPSMA, at SpectronRx’s Indiana facility. This agreement will enable the production of up to 400,000 patient-ready doses annually and facilitate distribution across the United States, significantly enhancing Clarity’s capacity to meet market demand upon successful completion of its Phase III trials and FDA approval. The partnership aims to leverage the benefits of copper-64’s optimal half-life to overcome logistical challenges associated with current-generation diagnostics, offering a more reliable and accessible diagnostic alternative for prostate cancer patients.

The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes. The company specializes in radiopharmaceuticals, particularly in the development of diagnostic and therapeutic agents for cancer patients.

Average Trading Volume: 2,949,967

Technical Sentiment Signal: Sell

Current Market Cap: A$694.1M

Learn more about CU6 stock on TipRanks’ Stock Analysis page.